{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:46:48Z","timestamp":1792090008423,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Moderate-risk gene variants represent an increasingly recognized component of hereditary breast and ovarian cancer (HBOC) predisposition, yet their clinical interpretation and management remain less standardized than those of high-penetrance genes. This study provides a seven-year real-world evaluation of genetic variants in\n                    <jats:italic>ATM<\/jats:italic>\n                    ,\n                    <jats:italic>BARD1<\/jats:italic>\n                    ,\n                    <jats:italic>CHEK2<\/jats:italic>\n                    ,\n                    <jats:italic>RAD51C<\/jats:italic>\n                    , and\n                    <jats:italic>RAD51D<\/jats:italic>\n                    in individuals undergoing germline testing at a specialized HBOC center, with a particular focus on variant distribution and associated clinical management. We retrospectively analyzed germline testing data from 3416 individuals evaluated at the HBOC center Erlangen between 2018 and 2024. Testing indications included predictive as well as diagnostic and therapeutic testing in the context of breast and gynecologic neoplasms. Variant classifications followed ACMG\/IARC (American College of Medical Genetics and Genomics\/ International Agency for Research on Cancer) criteria. Clinical recommendations, including participation in the intensified breast cancer surveillance (IBCS) program and risk-reducing surgery, were extracted from structured counseling documentation. (Likely) Pathogenic variants in moderate-risk genes were identified across all clinical subgroups.\n                    <jats:italic>CHEK2<\/jats:italic>\n                    represented the most frequently altered moderate-risk gene, followed by\n                    <jats:italic>ATM<\/jats:italic>\n                    . In contrast, (likely) pathogenic variants in\n                    <jats:italic>BARD1<\/jats:italic>\n                    ,\n                    <jats:italic>RAD51C<\/jats:italic>\n                    , and\n                    <jats:italic>RAD51D<\/jats:italic>\n                    were observed solely among individuals undergoing predictive testing or presenting with breast malignancies. A small subset of individuals carried more than one (likely) pathogenic variant in HBOC susceptibility genes. Most women with moderate-risk variants were enrolled in the IBCS program, although in justified cases participation was withheld based on patient-specific risk factors. An isolated moderate-risk variant generally did not warrant a recommendation for risk-reducing breast surgery. Risk-reducing salpingo-oophorectomy (RRSO) was primarily discussed with individuals harboring\n                    <jats:italic>RAD51C<\/jats:italic>\n                    or\n                    <jats:italic>RAD51D<\/jats:italic>\n                    variants. Individualized modifications to the recommendations were applied especially in cases with complex genotypes comprising multiple (likely) pathogenic variants. In conclusion, this study demonstrates considerable heterogeneity in germline variants among individuals evaluated for HBOC susceptibility and highlights the particular challenges associated with interpreting moderate-risk gene alterations. The findings underscore the importance of individualized clinical assessment and support the use of real-world data to inform evidence-based surveillance and prevention strategies in hereditary cancer care.\n                  <\/jats:p>","DOI":"10.1007\/s10689-026-00609-5","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:49:36Z","timestamp":1792086576000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Moderate-risk variants in hereditary breast and ovarian cancer: seven-year experience from a specialized center"],"prefix":"10.1007","volume":"25","author":[{"given":"Annika","family":"Kr\u00fcckel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias W.","family":"Beckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Br\u00fcckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Fasching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Gass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Gocke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin C.","family":"Hack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Heindl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"H\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emelie","family":"Kunze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"M\u00fcller-Wirtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Amann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"issue":"6","key":"609_CR1","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s12282-020-01148-2","volume":"28","author":"R Yoshida","year":"2021","unstructured":"Yoshida R (2021) Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis. Breast Cancer 28(6):1167\u20131180","journal-title":"Breast Cancer"},{"issue":"12","key":"609_CR2","doi-asserted-by":"publisher","first-page":"104350","DOI":"10.1016\/j.ejmg.2021.104350","volume":"64","author":"DH Marmolejo","year":"2021","unstructured":"Marmolejo DH, Wong MYZ, Bajalica-Lagercrantz S, Tischkowitz M, Balma\u00f1a J, Pat\u00f3cs AB, Chappuis P, Colas C, Genuardi M, Haanp\u00e4\u00e4 M (2021) Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe. Eur J Med Genet 64(12):104350","journal-title":"Eur J Med Genet"},{"key":"609_CR3","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2011.0323","author":"MP Lux","year":"2016","unstructured":"Lux MP, Bani MR, Fasching PA, Beckmann MW (2016) Hereditary breast and ovarian cancer. Mol Basis Hum Cancer. https:\/\/doi.org\/10.3238\/arztebl.2011.0323","journal-title":"Mol Basis Hum Cancer"},{"key":"609_CR4","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1200\/GO.21.00051","volume":"7","author":"S Gupta","year":"2021","unstructured":"Gupta S, Rajappa S, Advani S, Agarwal A, Aggarwal S, Goswami C, Palanki SD, Arya D, Patil S, Kodagali R (2021) Prevalence of BRCA1 and BRCA2 mutations among patients with ovarian, primary peritoneal, and fallopian tube cancer in India: a multicenter cross-sectional study. JCO Global Oncol 7:849\u2013861","journal-title":"JCO Global Oncol"},{"issue":"10","key":"609_CR5","doi-asserted-by":"publisher","first-page":"e0186043","DOI":"10.1371\/journal.pone.0186043","volume":"12","author":"P Harter","year":"2017","unstructured":"Harter P, Hauke J, Heitz F, Reuss A, Kommoss S, Marm\u00e9 F, Heimbach A, Prieske K, Richters L, Burges A (2017) Prevalence of deleterious germline variants in risk genes including BRCA1\/2 in consecutive ovarian cancer patients (AGO-TR-1). PLoS ONE 12(10):e0186043","journal-title":"PLoS ONE"},{"issue":"15","key":"609_CR6","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1200\/JCO.20.01200","volume":"39","author":"PA Fasching","year":"2021","unstructured":"Fasching PA, Yadav S, Hu C, Wunderle M, Haberle L, Hart SN, Rubner M, Polley EC, Lee KY, Gnanaolivu RD et al (2021) Mutations in BRCA1\/2 and other panel genes in patients with metastatic breast cancer -association with patient and disease characteristics and effect on prognosis. J Clin Oncol 39(15):1619\u20131630","journal-title":"J Clin Oncol"},{"issue":"1","key":"609_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00404-025-08270-6","volume":"313","author":"A Kruckel","year":"2026","unstructured":"Kruckel A, Gocke J, Horner M, Keller K, Muller C, Bruckner L, Heindl F, Hack CC, Beckmann MW, Amann N (2026) Genetic tumor syndromes in female cancer: insights into inherited cancer predisposition and clinical implications. Arch Gynecol Obstet 313(1):38","journal-title":"Arch Gynecol Obstet"},{"issue":"2","key":"609_CR8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000516376","volume":"17","author":"K Rhiem","year":"2022","unstructured":"Rhiem K, Auber B, Briest S, Dikow N, Ditsch N, Dragicevic N, Grill S, Hahnen E, Horvath J, Jaeger B (2022) Consensus recommendations of the German consortium for hereditary breast and ovarian cancer. Breast Care 17(2):199\u2013207","journal-title":"Breast Care"},{"issue":"1","key":"609_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.annonc.2022.10.004","volume":"34","author":"C Sessa","year":"2023","unstructured":"Sessa C, Balma\u00f1a J, Bober S, Cardoso M-J, Colombo N, Curigliano G, Domchek S, Evans D, Fischerova D, Harbeck N (2023) Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline\u2606. Ann Oncol 34(1):33\u201347","journal-title":"Ann Oncol"},{"issue":"11","key":"609_CR10","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/jnci\/dji141","volume":"97","author":"D Thompson","year":"2005","unstructured":"Thompson D, Duedal S, Kirner J, McGuffog L, Last J, Reiman A, Byrd P, Taylor M, Easton DF (2005) Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst 97(11):813\u2013822","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"609_CR11","doi-asserted-by":"publisher","first-page":"e176","DOI":"10.3747\/co.25.3707","volume":"25","author":"K Jerzak","year":"2018","unstructured":"Jerzak K, Mancuso T, Eisen A (2018) Ataxia\u2013telangiectasia gene (ATM) mutation heterozygosity in breast cancer: a narrative review. Curr Oncol 25(2):e176","journal-title":"Curr Oncol"},{"issue":"1","key":"609_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13058-019-1137-9","volume":"21","author":"N Weber-Lassalle","year":"2019","unstructured":"Weber-Lassalle N, Borde J, Weber-Lassalle K, Horvath J, Niederacher D, Arnold N, Kaulfuss S, Ernst C, Paul VG, Honisch E et al (2019) Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer. Breast Cancer Res 21(1):55","journal-title":"Breast Cancer Res"},{"key":"609_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41523-017-0024-8","volume":"3","author":"TP Slavin","year":"2017","unstructured":"Slavin TP, Maxwell KN, Lilyquist J, Vijai J, Neuhausen SL, Hart SN, Ravichandran V, Thomas T, Maria A, Villano D et al (2017) The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. NPJ Breast Cancer 3:22","journal-title":"NPJ Breast Cancer"},{"issue":"9","key":"609_CR14","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/jamaoncol.2017.0424","volume":"3","author":"FJ Couch","year":"2017","unstructured":"Couch FJ, Shimelis H, Hu C, Hart SN, Polley EC, Na J, Hallberg E, Moore R, Thomas A, Lilyquist J (2017) Associations between cancer predisposition testing panel genes and breast cancer. JAMA Oncol 3(9):1190\u20131196","journal-title":"JAMA Oncol"},{"issue":"28","key":"609_CR15","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1200\/JCO.2010.34.0778","volume":"29","author":"C Cybulski","year":"2011","unstructured":"Cybulski C, Wokolorczyk D, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Masojc B, Deebniak T, Gorski B, Blecharz P et al (2011) Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol 29(28):3747\u20133752","journal-title":"J Clin Oncol"},{"issue":"5","key":"609_CR16","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1913948","volume":"384","author":"C Breast Cancer Association","year":"2021","unstructured":"Breast Cancer Association C, Dorling L, Carvalho S, Allen J, Gonzalez-Neira A, Luccarini C, Wahlstrom C, Pooley KA, Parsons MT, Fortuno C et al (2021) Breast cancer risk genes - association analysis in more than 113,000 women. N Engl J Med 384(5):428\u2013439","journal-title":"N Engl J Med"},{"issue":"12","key":"609_CR17","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1093\/jnci\/djaa030","volume":"112","author":"X Yang","year":"2020","unstructured":"Yang X, Song H, Leslie G, Engel C, Hahnen E, Auber B, Horvath J, Kast K, Niederacher D, Turnbull C et al (2020) Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D. J Natl Cancer Inst 112(12):1242\u20131250","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"609_CR18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1200\/OP.21.00382","volume":"18","author":"YL Liu","year":"2022","unstructured":"Liu YL, Breen K, Catchings A, Ranganathan M, Latham A, Goldfrank DJ, Grisham RN, Long Roche K, Frey MK, Chi DS et al (2022) Risk-reducing bilateral salpingo-oophorectomy for ovarian cancer: a review and clinical guide for hereditary predisposition genes. JCO Oncol Pract 18(3):201\u2013209","journal-title":"JCO Oncol Pract"},{"key":"609_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8100404","author":"K Lhotova","year":"2020","unstructured":"Lhotova K, Stolarova L, Zemankova P, Vocka M, Janatova M, Borecka M, Cerna M, Jelinkova S, Kral J, Volkova Z et al (2020) Multigene panel germline testing of 1333 czech patients with ovarian cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/biomedicines8100404","journal-title":"Cancers (Basel)"},{"issue":"25","key":"609_CR20","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmana J et al (2021) Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med 384(25):2394\u20132405","journal-title":"N Engl J Med"},{"issue":"6","key":"609_CR21","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A et al (2017) Olaparib for metastatic breast cancer in patients with a Germline BRCA mutation. N Engl J Med 377(6):523\u2013533","journal-title":"N Engl J Med"},{"issue":"5","key":"609_CR22","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1055\/a-2515-2366","volume":"85","author":"D Luftner","year":"2025","unstructured":"Luftner D, Kolberg HC, Hartkopf AD, Fehm TN, Welslau M, Muller V, Schutz F, Fasching PA, Jackisch C, Marme F et al (2025) Update breast cancer 2024 part 3 - patients with advanced stage breast cancer. Geburtshilfe Frauenheilkd 85(5):507\u2013519","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"3","key":"609_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000545019","volume":"20","author":"TW Park-Simon","year":"2025","unstructured":"Park-Simon TW, Muller V, Albert US, Banys-Paluchowski M, Bartsch R, Bauerfeind I, Bjelic-Radisic V, Blohmer JU, Budach W, Dall P et al (2025) AGO recommendations for the diagnosis and treatment of patients with early breast cancer: Update 2025. Breast Care (Basel) 20(3):1\u201319","journal-title":"Breast Care (Basel)"},{"issue":"6","key":"609_CR24","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1055\/a-2562-8469","volume":"85","author":"S Lukac","year":"2025","unstructured":"Lukac S, Pfister K, Schaffler H, Leinert E, Fink A, Rack B, Fink V, Janni W, Heublein S (2025) Adjuvant targeted treatment of early hormone receptor-positive HER2-negative breast cancer: olaparib, abemaciclib or ribociclib - which one, how and for whom? Geburtshilfe Frauenheilkd 85(6):590\u2013598","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"11","key":"609_CR25","doi-asserted-by":"publisher","first-page":"101557","DOI":"10.1016\/j.gim.2025.101557","volume":"27","author":"J Ngeow","year":"2025","unstructured":"Ngeow J, Chiang J, Astiazaran-Symonds E, Balmana J, Cass I, Kommoss FKF, Foulkes WD, James PA, Katcher A, Klugman S et al (2025) Management of individuals with heterozygous germline pathogenic variants in RAD51C, RAD51D, and BRIP1: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med 27(11):101557","journal-title":"Genet Med"},{"issue":"1","key":"609_CR26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13048-020-00654-3","volume":"13","author":"M Suszynska","year":"2020","unstructured":"Suszynska M, Ratajska M, Kozlowski P (2020) BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~\u200930,000 cases. J Ovarian Res 13(1):50","journal-title":"J Ovarian Res"},{"issue":"12","key":"609_CR27","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1136\/jmedgenet-2022-108471","volume":"59","author":"A Lee","year":"2022","unstructured":"Lee A, Mavaddat N, Cunningham A, Carver T, Ficorella L, Archer S, Walter FM, Tischkowitz M, Roberts J, Usher-Smith J et al (2022) Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1 updates to tumour pathology and cancer incidence. J Med Genet 59(12):1206\u20131218","journal-title":"J Med Genet"},{"issue":"9","key":"609_CR28","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1038\/s41416-024-02851-z","volume":"131","author":"X Yang","year":"2024","unstructured":"Yang X, Wu Y, Ficorella L, Wilcox N, Dennis J, Tyrer J, Carver T, Pashayan N, Tischkowitz M, Pharoah PDP et al (2024) Validation of the BOADICEA model for epithelial tubo-ovarian cancer risk prediction in UK Biobank. Br J Cancer 131(9):1473\u20131479","journal-title":"Br J Cancer"},{"issue":"4","key":"609_CR29","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3109\/13697137.2015.1020484","volume":"18","author":"SS Faubion","year":"2015","unstructured":"Faubion SS, Kuhle CL, Shuster LT, Rocca WA (2015) Long-term health consequences of premature or early menopause and considerations for management. Climacteric 18(4):483\u2013491","journal-title":"Climacteric"},{"issue":"3","key":"609_CR30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1258\/mi.2008.008016","volume":"14","author":"LT Shuster","year":"2008","unstructured":"Shuster LT, Gostout BS, Grossardt BR, Rocca WA (2008) Prophylactic oophorectomy in premenopausal women and long-term health. Menopause Int 14(3):111\u2013116","journal-title":"Menopause Int"},{"issue":"11","key":"609_CR31","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.mayocp.2016.08.002","volume":"91","author":"WA Rocca","year":"2016","unstructured":"Rocca WA, Gazzuola-Rocca L, Smith CY, Grossardt BR, Faubion SS, Shuster LT, Kirkland JL, Stewart EA, Miller VM (2016) Accelerated Accumulation of Multimorbidity After Bilateral Oophorectomy: A Population-Based Cohort Study. Mayo Clin Proc 91(11):1577\u20131589","journal-title":"Mayo Clin Proc"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-026-00609-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10689-026-00609-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-026-00609-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:49:36Z","timestamp":1792086576000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10689-026-00609-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["609"],"URL":"https:\/\/doi.org\/10.1007\/s10689-026-00609-5","relation":{},"ISSN":["1573-7292"],"issn-type":[{"value":"1573-7292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"16 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.K. received lecture fees from Gilead and Novartis, honoraria for written scientific work from Thieme as well as support for attending meetings from Lilly; L.B. received lecture fees from Gilead, honoraria for written scientific work from Thieme as well as support for attending meetings from AstraZeneca; P.A.F. received personal fees from Novartis, grants from Biontech, grants and personal fees from Pfizer, personal fees from Daiichi-Sankyo, personal fees from Astra Zeneca, personal fees from Eisai, personal fees from Merck Sharp & Dohme, grants from Cepheid, personal fees from Lilly, personal fees from Seagen, personal fees from Roche, personal fees from Agendia, personal fees from Gilead, personal fees from Mylan, personal fees from Menarini, personal fees from Veracyte, personal fees from Guardant Health, and Translational Research in Oncology (TRIO).P.G. received honoraria Pfizer, Roche, Astra Zeneca, Novartis, Daiichi Sankyo und GSK; J.G. received support for attending meetings from AbbVie; C.C.H. received honoraria from Novartis, Roche, Pfizer, AstraZeneca, Daiichi Sankyo, Gilead, Eisai and MSD as well as support for attending meetings from Daiichi Sankyo, AstraZeneca and Gilead; F.H. received honoraria from AstraZeneca, Novartis, Lilly, and Bayer; M.H. received research support from Helsinn Healthcare SA, honoraria from Lilly Deutschland GmbH, Thieme and travel support from Novartis, Lilly Deutschland GmbH, and AstraZeneca; C.M.-W. received consulting fees from Novartis; N.A. received honoraria from Gilead, Novartis, Roche, Pfizer, Thieme as well as support for attending meetings from AstraZeneca and Pfizer.All remaining authors have nothing to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Faculty of Medicine at Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU) (ref. number 24-440-Br). All procedures were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Supplemental agreement to the study was waived due to the retrospective study design, including only anonymized data analysis. There was no use of animal research within this project.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"96"}}